


Supporting Information for**“A Facile and Modular Synthesis of Phosphinooxazoline (PHOX) Ligands”**

Kousuke Tani, Douglas C. Behenna, Ryan McFadden and Brian M. Stoltz

The Arnold and Mabel Beckman Laboratories of Chemical Synthesis, Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California 91125, USA

Materials and Methods. Unless otherwise stated, reactions were performed in flame-dried glassware under an argon or nitrogen atmosphere using dry deoxygenated solvents. Solvents were dried by passage through an activated alumina column under argon. Diphenylphosphine, di-*p*-tolylphosphine, dicyclohexylphosphine, and diisobutylphosphine were purchased from Strem Chemicals, Inc. and were used as received. Copper (I) iodide, *N,N'*-dimethylethylenediamine, cesium carbonate, 2-bromobenzoyl chloride, tetrafluoroboric acid solution and molecular sieves 4Å were purchased from Sigma-Aldrich Chemical Company and used as received. Bis-(4-(trifluoromethyl)phenyl)phosphine was prepared by the known method.¹ (S)-Leucinol and (S)-tryptophanol were purchased from Sigma-Aldrich Chemical Company and Chem-Impex International, Inc., respectively. The other starting chiral amino alcohols were prepared by the reduction of the corresponding amino acids,² which were purchased from Chem-Impex International, Inc. 2-Bromo-5-methoxybenzoyl chloride and 2-bromo-5-(trifluoromethyl)-benzoyl chloride were prepared from the corresponding benzoic acid derivatives.³ Reaction temperatures were controlled by an IKA mag temperature modulator. Thin-layer chromatography (TLC) was performed using E. Merck silica gel 60 F254 precoated plates (0.25 mm) and visualized by UV fluorescence quenching, anisaldehyde, CAM, or KMnO₄ staining. ICN Silica gel (particle size 0.032–0.063 mm) was used for flash chromatography. Optical rotations were measured with a Jasco P-1010 polarimeter at 589 nm. ¹H, ¹³C, ³¹P and ¹⁹F NMR spectra were recorded on a Varian Mercury 300 (at 300 MHz, 75 MHz, 121 MHz and 282 MHz, respectively). ¹H NMR spectra are reported relative to Me₄Si (δ 0.0 ppm) or residual CHCl₃ (δ 7.26 ppm) or CHD₂CN (δ 1.94 ppm). Data for ¹H NMR spectra are reported as follows: chemical shift (δ ppm) (multiplicity, coupling constant (Hz), integration). Multiplicities are reported as follows: s = singlet, d = doublet, t = triplet, q = quartet, sept. = septet, m = multiplet, comp. m = complex multiplet, app. = apparent, bs = broad singlet. ¹³C NMR were reported relative to CDCl₃ (δ 77.0 ppm) and CD₃CN (δ 1.39 ppm), respectively. ¹⁹F NMR spectra were reported relative to CFCl₃ (δ 0.0 ppm). ³¹P NMR spectra were reported relative to external H₃PO₄ (δ 0.0 ppm). FTIR spectra were recorded on a Perkin Elmer Paragon 1000 spectrometer and are reported in frequency of absorption (cm⁻¹). High resolution mass spectra were obtained from the Caltech Mass Spectral Facility.


General Procedure for the Synthesis of Aryl Bromide Precursors




(S)-2-Bromo-N-(1-hydroxy-3,3-dimethylbutan-2-yl)benzamide (SI1). To a solution of (S)-t-leucinol (3.57 g, 30.5 mmol, 1.0 equiv) in DCM (100 mL) was added a solution of Na₂CO₃ (9.70 g, 91.5 mmol, 3.0 equiv) in water (75.0 mL). To the vigorously stirred biphasic mixture was added 2-bromobenzoyl chloride (4.58 mL, 35.1 mmol, 1.15 equiv) in a dropwise manner. After 12 h at ambient temperature, the layers were separated, and the aqueous layer was extracted with DCM (2 x 50 mL). The combined organics were treated with KOH (15 mL of a 1 M methanolic solution) for 15 min, neutralized with 3 M HCl, and water (50 mL) was added. The layers were separated, and the aqueous layer extracted with DCM (2 x 50 mL). The combined organics were dried (Na₂SO₄), evaporated, and the residue chromatographed (25 to 35% acetone in hexanes on SiO₂) to give amide **SI1** (8.19 g, 89.5% yield): mp 50.0–51.0 °C from acetone/hexanes; ¹H NMR (300 MHz, CDCl₃) δ 7.58 (dd, *J* = 7.8, 0.9 Hz, 1H), 7.54 (dd, *J* = 7.5, 1.8 Hz, 1H), 7.34 (app. dt, *J* = 7.4, 1.1 Hz, 1H), 7.26 (app. dt, *J* = 7.7, 1.8 Hz, 1H), 6.24 (bd, *J* = 8.1 Hz, 1H), 4.05 (m, 1H), 3.93 (dd, *J* = 11.4, 3.6 Hz, 1H), 3.66 (dd, *J* = 11.4, 7.5 Hz, 1H), 2.68 (bs, 1H), 1.03 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 168.7, 137.9, 133.3, 131.2, 129.7, 127.6, 119.0, 62.9, 60.2, 33.8, 27.1; FTIR (Neat Film NaCl) 3245, 3070, 2963, 1640, 1557 cm⁻¹; HRMS (FAB, Pos.) *m/z* calc'd for C₁₃H₁₉NO₂Br [M+H]⁺: 300.0599, found 300.0590; [α]_D²⁹ +20.2 (*c* 2.38, methanol, >99 % ee).

(S)-2-(2-Bromophenyl)-4-tert-butyl-4,5-dihydrooxazole⁴ (SI2). A solution of amide **SI1** (8.10 g, 27.0 mmol, 1.0 equiv), *p*-toluenesulfonyl chloride (6.69 g, 35.1 mmol, 1.3 equiv), triethylamine (18.7 mL, 135.0 mmol, 5.0 equiv) in DCM (200 mL) in a round bottom flask equipped with a reflux condenser was heated at 55 °C for 22 h. At which time, water (28 mL) was added and heating continued at 75 °C for 2 h. The reaction mixture was cooled, the layers separated, and the aqueous layer extracted with DCM (2 x 25 mL). The combined organics were dried (Na₂SO₄), evaporated, and the residue chromatographed (5% EtOAc in hexanes on SiO₂) to give phenyloxazoline **SI2** (6.19 g, 81.2% yield): ¹H NMR (300 MHz, CDCl₃) δ 7.64 (app. dt, *J* = 8.7, 1.7 Hz, 2H), 7.33 (app. dt, *J* = 7.7, 1.5 Hz, 1H), 7.26 (m, 1H), 4.38 (dd, *J* = 10.5, 8.9 Hz, 1H), 4.25 (app. t, *J* = 8.3 Hz, 1H), 4.10 (dd, *J* = 10.2, 8.1 Hz, 1H), 1.00 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 162.8, 133.6, 131.4, 131.2, 130.2, 127.0, 121.8, 76.6, 69.0, 34.0, 25.9; FTIR (Neat Film NaCl) 2956, 1661, 1478, 1354, 1099, 1022, 963 cm⁻¹; HRMS (FAB Pos.) *m/z* calc'd for C₁₃H₁₇NOBr [M+H]⁺: 282.0493, found 282.0488; [α]_D²⁹ -48.3 (*c* 3.77, hexane, >99 % ee).


The following aryl bromides were synthesized from the corresponding chiral amino alcohols and 2-bromobenzoyl chlorides by the same manner as described above.




(R)-2-(2-Bromophenyl)-4-cyclohexyl-4,5-dihydrooxazole. White powder; mp 132–134 °C; $R_f = 0.50$ (hexanes/EtOAc, 4/1); ^1H NMR (300 MHz, CDCl_3) δ 7.67 (dd, $J = 7.4, 1.9$ Hz, 1H), 7.63 (dd, $J = 7.7, 1.4$ Hz, 1H), 7.33 (td, $J = 7.4, 1.4$ Hz, 1H), 7.27 (td, $J = 7.7, 2.2$ Hz, 1H), 5.44 (m, 1H), 4.17 (m, 2H), 1.97 (d, $J = 12.7$ Hz, 1H), 1.73 (m, 4H), 1.58 (m, 1H), 1.17 (m, 5H); ^{13}C NMR (75 MHz, CDCl_3) δ 163.0, 133.9, 131.6, 131.5, 127.2, 121.9, 72.3, 70.7, 42.8, 29.6, 29.0, 26.7, 26.3; FTIR (Neat Film NaCl) 2924, 1640, 1537, 1468, 1328, 1057, 1026 cm^{-1} ; HRMS (EI) m/z calc'd for $\text{C}_{15}\text{H}_{18}\text{NOBr} [\text{M}^+]$: 307.0572, found 307.0581; $[\alpha]_D^{25} = +14.5$ (c 0.125, CHCl_3).




(S)-4-(1-Adamantyl)-2-(2-bromophenyl)-4,5-dihydrooxazole. White wax; $R_f = 0.43$ (hexanes/Et₂O, 3/1); ^1H NMR (300 MHz, CDCl_3) δ 7.68–7.60 (m, 2H), 7.36–7.23 (m, 2H), 4.39–4.26 (m, 2H), 3.94 (m, 1H), 2.01 (m, 3H), 1.80–1.63 (m, 10H), 1.58–1.50 (m, 2H); ^{13}C NMR (75 MHz, CDCl_3) δ 162.6, 133.7, 131.4, 131.3, 130.3, 127.0, 121.8, 76.8, 67.5, 38.6, 37.1, 35.7, 28.2; FTIR (Neat Film NaCl) 2902, 2848, 1659, 1591, 1478, 1449, 1346, 1308, 1246, 1095, 1022, 960, 764, 731 cm^{-1} ; HRMS (FAB, Pos.) m/z calc'd for $\text{C}_{19}\text{H}_{23}\text{BrNO} [\text{M}+\text{H}]^+$: 360.0963, found 360.0958; $[\alpha]_D^{26} = -80.8$ (c 1.12, CHCl_3).




(S)-2-(2-Bromophenyl)-4-neopentyl-4,5-dihydrooxazole. Colorless oil; $R_f = 0.48$ (hexanes/Et₂O, 3/1); ^1H NMR (300 MHz, CDCl_3) δ 7.67 (dd, $J = 7.8, 1.5$ Hz, 1H), 7.62 (dd, $J = 7.8, 1.5$ Hz, 1H), 7.32 (td, $J = 7.8, 1.5$ Hz, 1H), 7.26 (td, $J = 7.8, 1.5$ Hz, 1H), 4.57 (dd, $J = 9.3, 8.1$ Hz, 1H), 4.35 (m, 1H), 3.99 (t, $J = 8.1$ Hz, 1H), 1.92 (dd, $J = 13.8, 4.8$ Hz, 1H), 1.47 (dd, $J = 13.8, 7.8$ Hz, 1H), 1.00 (s, 9H); ^{13}C NMR (75 MHz, CDCl_3) δ 162.3, 133.7, 131.5, 131.3, 130.0, 127.0, 121.8, 74.5, 64.5, 50.5, 30.3, 30.0; FTIR (Neat Film NaCl) 2955, 1654, 1592, 1475, 1431, 1356, 1244, 1093, 1026, 966, 765, 730 cm^{-1} ; HRMS (FAB, Pos.) m/z calc'd for $\text{C}_{14}\text{H}_{19}\text{BrNO} [\text{M}+\text{H}]^+$: 296.0650, found 296.0660; $[\alpha]_D^{26} = -47.7$ (c 1.04, CHCl_3).



(S)-4-(2-(Benzyl)propan-2-yl)-2-(2-bromophenyl)-4,5-dihydrooxazole. White solid; mp 54–56 °C; R_f = 0.26 (hexanes/Et₂O, 3/1); ¹H NMR (300 MHz, CDCl₃) δ 7.69–7.62 (m, 2H), 7.37–7.24 (m, 7H), 4.65–4.39 (m, 5H), 1.49 (s, 3H), 1.31 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 164.0, 139.4, 133.7, 131.6, 131.3, 130.0, 128.3, 127.2, 127.14, 127.07, 121.8, 77.0, 75.1, 69.2, 64.0, 24.0, 20.1; FTIR (Neat Film NaCl) 3064, 3031, 2975, 2906, 1654, 1590, 1474, 1454, 1435, 1386, 1354, 1244, 1155, 1100, 1064, 1027, 960, 735 cm⁻¹; HRMS (FAB, Pos.) *m/z* calc'd for C₁₉H₂₁BrNO₂ [M+H]⁺: 374.0756, found 374.0748; [α]_D²⁶ = +18.1 (c 1.04, CHCl₃).




(S)-2-(2-Bromophenyl)-4-(2-(tert-butyldimethylsilyloxy)propan-2-yl)-4,5-dihydrooxazole. Colorless oil; R_f = 0.52 (hexanes/Et₂O, 3/1); ¹H NMR (300 MHz, CDCl₃) δ 7.67 (dd, *J* = 7.5, 2.1 Hz, 1H), 7.62 (dd, *J* = 7.5, 1.2 Hz, 1H), 7.32 (td, *J* = 7.5, 1.2 Hz, 1H), 7.26 (td, *J* = 7.5, 2.1 Hz, 1H), 4.52 (dd, *J* = 8.4, 7.2 Hz, 1H), 4.39 (dd, *J* = 10.2, 8.4 Hz, 1H), 4.22 (dd, *J* = 10.2, 7.2 Hz, 1H), 1.39 (s, 3H), 1.29 (s, 3H), 0.84 (s, 9H), 0.114 (s, 3H), 0.111 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 163.7, 133.8, 131.5, 131.3, 130.0, 127.0, 121.8, 77.0, 74.8, 69.3, 28.8, 25.7, 24.7, 18.0, -2.1, -2.2; FTIR (Neat Film NaCl) 2956, 2929, 2856, 1656, 1591, 1472, 1435, 1381, 1355, 1253, 1187, 1162, 1101, 1053, 835, 773 cm⁻¹; HRMS (FAB, Pos.) *m/z* calc'd for C₁₈H₂₉BrNO₂Si [M+H]⁺: 398.1151, found 398.1150; [α]_D²⁶ = +37.4 (c 1.01, CHCl₃).




(S)-2-(2-Bromophenyl)-4-(naphthalen-1-ylmethyl)-4,5-dihydrooxazole. Colorless oil; R_f = 0.44 (hexanes/EtOAc, 3/1); ¹H NMR (300 MHz, CDCl₃) δ 8.18 (d, *J* = 8.4 Hz, 1H), 7.88 (m, 1H), 7.78 (dd, *J* = 7.2, 2.4 Hz, 1H), 7.70–7.64 (m, 2H), 7.60–7.26 (m, 6H), 4.84 (m, 1H), 4.36–4.23 (m, 2H), 3.84 (dd, *J* = 14.1, 4.8 Hz, 1H), 3.12 (dd, *J* = 14.1, 9.3 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 163.5, 134.0, 133.80, 133.76, 132.0, 131.6, 131.3, 129.9, 128.8, 127.5, 127.1, 127.0, 126.1, 125.7, 125.4, 123.8, 121.8, 72.2, 67.2, 38.9; FTIR (Neat Film NaCl) 3057, 1653, 1590, 1476, 1430, 1355, 1087, 1024, 960, 780, 729


cm^{-1} ; HRMS (FAB, Pos.) m/z calc'd for $\text{C}_{20}\text{H}_{17}\text{BrNO} [\text{M}+\text{H}]^+$: 366.0493, found 366.0471; $[\alpha]^{26}_D = -10.4$ (c 1.08, CHCl_3).



(S)-2-(2-Bromophenyl)-4-(naphthalen-2-ylmethyl)-4,5-dihydrooxazole. Colorless oil; $R_f = 0.37$ (hexanes/EtOAc, 3/1); ^1H NMR (300 MHz, CDCl_3) δ 7.84-7.78 (m, 3H), 7.73 (br s, 1H), 7.68-7.63 (m, 2H), 7.51-7.41 (m, 3H), 7.37-7.28 (m, 2H), 4.75 (m, 1H), 4.39 (dd, $J = 9.3, 8.4$ Hz, 1H), 4.24 (dd, $J = 8.4, 7.5$ Hz, 1H), 3.42 (dd, $J = 13.8, 5.1$ Hz, 1H), 2.99 (dd, $J = 13.8, 8.4$ Hz, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 163.4, 135.2, 133.8, 133.5, 132.3, 131.6, 131.2, 129.8, 128.2, 127.74, 127.70, 127.6, 127.5, 127.0, 126.0, 125.5, 121.8, 71.9, 68.1, 41.7; FTIR (Neat Film NaCl) 3054, 2896, 1650, 1590, 1508, 1477, 1431, 1356, 1244, 1097, 1024, 962, 818, 756, 729 cm^{-1} ; HRMS (FAB, Pos.) m/z calc'd for $\text{C}_{20}\text{H}_{17}\text{BrNO} [\text{M}+\text{H}]^+$: 366.0493, found 366.0484; $[\alpha]^{26}_D = +2.0$ (c 0.92, CHCl_3).




(S)-2-(2-Bromophenyl)-4-phenethyl-4,5-dihydrooxazole. Colorless oil; $R_f = 0.43$ (hexanes/EtOAc, 3/1); ^1H NMR (300 MHz, CDCl_3) δ 7.70-7.62 (m, 2H), 7.38-7.17 (m, 7H), 4.50 (dd, $J = 9.3, 8.1$ Hz, 1H), 4.36 (m, 1H), 4.08 (t, $J = 8.1$ Hz, 1H), 2.94-2.74 (m, 2H), 2.09 (m, 1H), 1.94 (m, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 163.0, 141.6, 133.7, 131.5, 131.2, 130.0, 128.43, 128.40, 127.1, 125.9, 121.8, 72.6, 66.5, 37.6, 32.2; FTIR (Neat Film NaCl) 2924, 1653, 1590, 1476, 1430, 1355, 1096, 1024, 962, 764, 730, 700 cm^{-1} ; HRMS (FAB, Pos.) m/z calc'd for $\text{C}_{17}\text{H}_{17}\text{BrNO} [\text{M}+\text{H}]^+$: 330.0493, found 330.0480; $[\alpha]^{24}_D = -70.7$ (c 1.14, CHCl_3).




(S)-2-(2-Bromophenyl)-4-(2-methylbenzyl)-4,5-dihydrooxazole. White solid; mp 53-55 °C; $R_f = 0.43$ (hexanes/EtOAc, 3/1); ^1H NMR (300 MHz, CDCl_3) δ 7.70 (dd, $J = 7.5, 2.1$ Hz, 1H), 7.65 (dd, $J = 7.5, 1.2$ Hz, 1H), 7.35 (td, $J = 7.5, 1.2$ Hz, 1H), 7.30 (td, $J = 7.5, 2.1$ Hz, 1H), 7.25-7.14 (m, 4H), 4.66 (m, 1H), 4.41 (t, $J = 8.7$ Hz, 1H), 4.21 (dd, $J = 8.7, 7.5$ Hz, 1H), 3.29 (dd, $J = 14.1, 5.4$ Hz, 1H), 2.79 (dd, $J = 14.1, 9.0$ Hz, 1H), 2.40 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 163.3, 136.4, 136.1, 133.7, 131.5, 131.2, 130.4, 129.8,


129.5, 127.0, 126.6, 126.0, 121.7, 72.1, 66.9, 38.9, 19.7; FTIR (Neat Film NaCl) 2954, 1653, 1590, 1476, 1436, 1355, 1244, 1097, 1025, 962, 765, 730 cm^{-1} ; HRMS (FAB, Pos.) m/z calc'd for $\text{C}_{17}\text{H}_{17}\text{BrNO}$ [M+H] $^{+}$: 330.0493, found 330.0501; $[\alpha]^{24}_{\text{D}} = -18.7$ (c 1.03, CHCl_3).



(S)-2-(2-Bromophenyl)-4-(2-(trifluoromethyl)benzyl)-4,5-dihydrooxazole. Colorless oil; $R_f = 0.52$ (hexanes/EtOAc, 3/1); ^1H NMR (300 MHz, CDCl_3) δ 7.72-7.63 (m, 3H), 7.59 (m, 1H), 7.51 (m, 1H), 7.39-7.26 (m, 3H), 4.68 (m, 1H), 4.50 (t, $J = 8.4$ Hz, 1H), 4.15 (t, $J = 8.4$ Hz, 1H), 3.27 (dd, $J = 14.7, 7.2$ Hz, 1H), 3.12 (ddd, $J = 14.7, 6.3, 1.2$ Hz, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 163.5, 136.6 (q, $J_{\text{CF}} = 1$ Hz), 133.7, 132.1, 131.8, 131.7, 131.2, 129.7, 128.8 (q, $J_{\text{CF}} = 29$ Hz), 127.1, 126.6, 126.0 (q, $J_{\text{CF}} = 6$ Hz), 124.5 (q, $J_{\text{CF}} = 272$ Hz), 121.8, 72.1, 67.5, 38.1 (q, $J_{\text{CF}} = 1$ Hz); FTIR (Neat Film NaCl) 3068, 2897, 1653, 1591, 1478, 1457, 1432, 1357, 1314, 1161, 1117, 1061, 1040, 964, 766, 730, 654 cm^{-1} ; HRMS (FAB, Pos.) m/z calc'd for $\text{C}_{17}\text{H}_{14}\text{BrF}_3\text{NO}$ [M+H] $^{+}$: 384.0211, found 384.0216; $[\alpha]^{25}_{\text{D}} = -72.7$ (c 0.85, CHCl_3).




(R)-4-Benzhydryl-2-(2-bromophenyl)-4,5-dihydrooxazole. White solid; mp 73-74 $^{\circ}\text{C}$; $R_f = 0.52$ (hexanes/EtOAc, 3/1); ^1H NMR (300 MHz, CDCl_3) δ 7.62-7.55 (m, 2H), 7.39-7.15 (m, 12H), 5.18 (m, 1H), 4.49 (t, $J = 6.0$ Hz, 1H), 4.22-4.12 (m, 2H); ^{13}C NMR (75 MHz, CDCl_3) δ 163.6, 142.0, 141.8, 133.6, 131.5, 131.3, 129.9, 128.70, 128.67, 128.4, 127.0, 126.8, 126.5, 121.9, 71.5, 70.5, 56.7; FTIR (Neat Film NaCl) 3026, 1654, 1559, 1540, 1496, 1474, 1450, 1356, 1097, 1024, 963, 701 cm^{-1} ; HRMS (FAB, Pos.) m/z calc'd for $\text{C}_{22}\text{H}_{19}\text{BrNO}$ [M+H] $^{+}$: 392.0650, found 392.0641; $[\alpha]^{25}_{\text{D}} = +49.9$ (c 0.68, CHCl_3).




(R)-2-(2-Bromophenyl)-4-(3,5-di-tert-butylbenzyl)-4,5-dihydrooxazole. Colorless oil; $R_f = 0.57$ (hexanes/EtOAc, 3/1); ^1H NMR (300 MHz, CDCl_3) δ 7.69 (dd, $J = 7.5, 2.1$


Hz, 1H), 7.65 (dd, J = 7.5, 1.5 Hz, 1H), 7.38-7.28 (m, 3H), 7.10 (d, J = 1.8 Hz, 2H), 4.64 (m, 1H), 4.39 (t, J = 8.4 Hz, 1H), 4.22 (dd, J = 8.4, 7.2 Hz, 1H), 3.27 (dd, J = 13.5, 4.8 Hz, 1H), 2.77 (dd, J = 13.5, 9.0 Hz, 1H), 1.34 (s, 18H); ^{13}C NMR (75 MHz, CDCl_3) δ 163.1, 150.8, 136.8, 133.8, 131.5, 131.3, 129.7, 127.0, 123.4, 121.8, 120.5, 72.0, 68.4, 42.1, 34.7, 31.4; FTIR (Neat Film NaCl) 2963, 1654, 1598, 1476, 1362, 1247, 1098, 1023, 964 cm^{-1} ; HRMS (FAB, Pos.) m/z calc'd for $\text{C}_{24}\text{H}_{31}\text{BrNO} [\text{M}+\text{H}]^+$: 428.1589, found 428.1597; $[\alpha]^{25}_{\text{D}} = -3.8$ (c 1.04, CHCl_3).




(S)-4-(Benzo[b]thiophen-3-ylmethyl)-2-(2-bromophenyl)-4,5-dihydrooxazole. Pale yellow oil; R_f = 0.45 (hexanes/EtOAc, 3/1); ^1H NMR (300 MHz, CDCl_3) δ 7.90-7.84 (m, 2H), 7.67-7.63 (m, 2H), 7.45-7.26 (m, 5H), 4.81 (m, 1H), 4.44 (dd, J = 9.3, 8.7 Hz, 1H), 4.22 (dd, J = 8.7, 7.2 Hz, 1H), 3.46 (ddd, J = 14.7, 4.8, 1.2 Hz, 1H), 3.06 (ddd, J = 14.7, 8.4, 0.9 Hz, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 163.5, 140.4, 138.9, 133.8, 132.3, 131.7, 131.3, 129.7, 127.1, 124.3, 124.0, 123.1, 122.9, 121.8, 121.7, 72.3, 66.5, 34.4; FTIR (Neat Film NaCl) 3067, 2895, 1653, 1590, 1476, 1427, 1357, 1314, 1287, 1250, 1095, 1022, 961, 758, 728 cm^{-1} ; HRMS (FAB, Pos.) m/z calc'd for $\text{C}_{18}\text{H}_{15}\text{BrNOS} [\text{M}+\text{H}]^+$: 372.0058, found 372.0064; $[\alpha]^{25}_{\text{D}} = -1.3$ (c 0.62, CHCl_3).



(S)-4-((1H-Indol-3-yl)methyl)-2-(2-bromophenyl)-4,5-dihydrooxazole. Pale yellow powder; mp 143-145 °C; R_f = 0.17 (hexanes/EtOAc, 3/1); ^1H NMR (300 MHz, CDCl_3) δ 8.20 (br s, 1H), 7.72-7.62 (m, 3H), 7.38-7.06 (m, 6H), 4.77 (m, 1H), 4.39 (dd, J = 9.3, 8.7 Hz, 1H), 4.22 (dd, J = 8.7, 7.5 Hz, 1H), 3.39 (ddd, J = 14.7, 5.1, 1.2 Hz, 1H), 2.97 (dd, J = 14.7, 8.7 Hz, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 163.3, 136.2, 133.7, 131.6, 131.3, 129.9, 127.6, 127.1, 122.5, 122.1, 121.8, 119.4, 118.8, 111.8, 111.1, 72.4, 67.3, 31.2; FTIR (Neat Film NaCl) 3413, 3217, 3057, 2923, 1652, 1590, 1477, 1456, 1433, 1358, 1243, 1099, 1025, 957, 743 cm^{-1} ; HRMS (FAB, Pos.) m/z calc'd for $\text{C}_{18}\text{H}_{16}\text{BrN}_2\text{O} [\text{M}+\text{H}]^+$: 355.0446, found 355.0448; $[\alpha]^{25}_{\text{D}} = -1.0$ (c 0.62, CHCl_3).




(S)-2-(2-Bromo-5-methoxyphenyl)-4-*tert*-butyl-4,5-dihydrooxazole. White powder; mp 41–43 °C; $R_f = 0.52$ (hexanes/Et₂O, 3/1); ¹H NMR (300 MHz, CDCl₃) δ 7.50 (d, $J = 9.0$ Hz, 1H), 7.19 (d, $J = 3.0$ Hz, 1H), 6.84 (dd, $J = 9.0, 3.0$ Hz, 1H), 4.38 (dd, $J = 10.2, 8.7$ Hz, 1H), 4.26 (t, $J = 8.3$ Hz, 1H), 4.10 (dd, $J = 10.2, 8.1$ Hz, 1H), 3.81 (s, 3H), 1.00 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 162.6, 158.5, 134.4, 130.7, 117.9, 116.1, 112.1, 76.6, 69.0, 55.6, 34.0, 25.9; FTIR (Neat Film NaCl) 2957, 1662, 1594, 1571, 1476, 1410, 1364, 1336, 1290, 1224, 1181, 1102, 1040, 1016, 969, 816 cm⁻¹; HRMS (EI) *m/z* calc'd for C₁₄H₁₈BrNO₂ [M⁺]: 311.0521, found 311.0536; [α]_D²⁴ = -64.4 (*c* 1.08, CHCl₃).



(S)-2-(2-Bromo-5-(trifluoromethyl)phenyl)-4-*tert*-butyl-4,5-dihydrooxazole. White powder; mp 32–33 °C; $R_f = 0.42$ (hexanes/Et₂O, 9/1); ¹H NMR (300 MHz, CDCl₃) δ 7.93 (d, $J = 2.4$ Hz, 1H), 7.78 (d, $J = 8.4$ Hz, 1H), 7.52 (dd, $J = 8.4, 2.4$ Hz, 1H), 4.42 (dd, $J = 10.2, 9.0$ Hz, 1H), 4.29 (t, $J = 8.3$ Hz, 1H), 4.14 (dd, $J = 10.2, 8.1$ Hz, 1H), 1.01 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 161.5, 134.5, 130.9, 129.8 (q, $J_{CF} = 33$ Hz), 128.2 (q, $J_{CF} = 4$ Hz), 127.9 (q, $J_{CF} = 4$ Hz), 125.9 (q, $J_{CF} = 1$ Hz), 123.4 (q, $J_{CF} = 271$ Hz), 76.9, 69.2, 34.0, 25.9; FTIR (Neat Film NaCl) 2959, 1662, 1607, 1479, 1341, 1325, 1298, 1262, 1242, 1174, 1134, 1082, 1028, 966, 912, 830 cm⁻¹; HRMS (EI) *m/z* calc'd for C₁₄H₁₅BrF₃NO [M⁺]: 349.0289, found 349.0299; [α]_D²⁵ = -64.7 (*c* 1.26, CHCl₃).


General Procedure for the Copper Catalyzed Synthesis of PHOX Ligands




(S)-4-*tert*-Butyl-2-(2-(diphenylphosphino)phenyl)-4,5-dihydrooxazole (S)-t-Bu-PHOX. A mixture of copper(I) iodide (338.3 mg, 1.77 mmol, 0.125 equiv), diphenylphosphine (4.64 mL, 26.7 mmol, 1.88 equiv), *N,N'*-dimethylethylenediamine

(1.32 mL, 12.4 mmol, 0.875 equiv) in toluene (60 mL) was stirred for 20 min at ambient temperature. At which point, phenyloxazoline **SI2** (4.00 g, 14.2 mmol, 1.00 equiv), cesium carbonate (17.4 g, 53.3 mmol, 3.75 equiv), and toluene (60 mL) were added, the flask sealed and heated to 110 °C with stirring. After 6 h, the reaction mixture was allowed to cool to ambient temperature, filtered, and the filter cake was washed with DCM (2 x 50 mL). Evaporation of the solvent and chromatography (3 to 7 % Et₂O in hexanes on SiO₂) afforded the known⁵ (*S*)-*t*-Bu-PHOX (4.48 g, 81 % yield).


The following PHOX derivatives were synthesized from the corresponding aryl bromides and diarylphosphines by the procedure described above.




(R)-4-Cyclohexyl-2-(2-(diphenylphosphino)phenyl)-4,5-dihydrooxazole. White solid; mp 122-124 °C; R_f = 0.57 (hexanes/EtOAc, 4/1); ¹H NMR (300 MHz, CDCl₃) δ 7.87 (ddd, J = 7.7, 4.1, 1.7 Hz, 1H), 7.27 (m, 13H), 6.82 (ddd, J = 7.7, 4.1, 1.1 Hz, 1H), 4.12 (ddd, J = 14.6, 9.1, 1.4 Hz, 1H), 3.85 (t, J = 8.3 Hz, 1H), 3.81 (t, J = 8.5 Hz, 1H), 1.60 (m, 4H), 1.28 (d, J = 13.5 Hz, 1H), 1.05 (m, 4H), 0.80 (m, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 162.7 (d, J_{CP} = 3 Hz), 138.0-139.0 (6 lines), 134.5 (d, J_{CP} = 21 Hz), 133.8, 133.7 (d, J_{CP} = 20 Hz), 131.8 (d, J_{CP} = 19 Hz), 130.4, 129.8 (d, J_{CP} = 3 Hz), 128.6-128.0 (7 lines), 71.2, 70.1, 42.7, 29.4, 29.0, 26.4, 26.1, 26.0; ³¹P NMR (121 MHz, CDCl₃) δ -4.21; FTIR (Neat Film NaCl) 3053, 2923, 2852, 1651, 1478, 1434, 1356, 1089, 1044, 964, 908 cm⁻¹; HRMS (EI) *m/z* calc'd for C₂₇H₂₈NOP [M⁺]: 413.1909, found 413.1923; [α]_D²⁵ = +47.9 (c 0.175, CHCl₃).




(S)-4-(1-Adamantyl)-2-(2-(diphenylphosphino)phenyl)-4,5-dihydrooxazole. White solid; mp 163-164 °C; R_f = 0.59 (hexanes/EtOAc, 5/1); ¹H NMR (300 MHz, CDCl₃) δ 7.93 (m, 1H), 7.40-7.20 (m, 12H), 6.85 (m, 1H), 4.11 (t, J = 9.0 Hz, 1H), 4.03 (t, J = 9.0 Hz, 1H), 3.73 (t, J = 9.0 Hz, 1H), 1.85 (m, 3H), 1.68-1.46 (m, 6H), 1.44-1.34 (m, 3H), 1.24-1.14 (m, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 162.4 (d, J_{CP} = 3 Hz), 138.8-138.3 (6 lines), 134.4 (d, J_{CP} = 21 Hz), 134.1, 133.4 (d, J_{CP} = 20 Hz), 132.0 (d, J_{CP} = 20 Hz), 130.3, 129.7 (d, J_{CP} = 3 Hz), 128.5-128.0 (7 lines), 76.8, 66.8, 38.2, 37.0, 35.3, 28.1; ³¹P NMR (121 MHz, CDCl₃) δ -5.67; FTIR (Neat Film NaCl) 3053, 2902, 2848, 1651, 1586, 1477, 1434, 1346, 1248, 1089, 1044, 1026, 963, 744, 696 cm⁻¹; HRMS (FAB, Pos.) *m/z* calc'd for C₃₁H₃₃NOP [M+H]⁺: 466.2300, found 466.2309; [α]_D²⁷ = -31.8 (c 0.48, CHCl₃).



(S)-2-(2-(Diphenylphosphino)phenyl)-4-neopentyl-4,5-dihydrooxazole. White solid; mp 83-86 °C; $R_f = 0.52$ (hexanes/EtOAc, 5/1); ^1H NMR (300 MHz, CDCl_3) δ 7.85 (ddd, $J = 7.8, 3.6, 1.5$ Hz, 1H), 7.38-7.23 (m, 12H), 6.84 (ddd, $J = 7.8, 4.5, 1.5$ Hz, 1H), 4.25 (dd, $J = 9.3, 8.1$ Hz, 1H), 4.03 (m, 1H), 3.58 (t, $J = 8.1$ Hz, 1H), 1.52 (dd, $J = 14.1, 4.5$ Hz, 1H), 0.93 (dd, $J = 14.1, 8.1$ Hz, 1H), 0.84 (s, 9H); ^{13}C NMR (75 MHz, CDCl_3) δ 163.0 (d, $J_{\text{CP}} = 3$ Hz), 138.7 (d, $J_{\text{CP}} = 25$ Hz), 137.9 (d, $J_{\text{CP}} = 12$ Hz), 137.8 (d, $J_{\text{CP}} = 10$ Hz), 134.3 (d, $J_{\text{CP}} = 21$ Hz), 133.9 (d, $J_{\text{CP}} = 21$ Hz), 133.5 (d, $J_{\text{CP}} = 2$ Hz), 131.8 (d, $J_{\text{CP}} = 18$ Hz), 130.3, 129.8 (d, $J_{\text{CP}} = 3$ Hz), 128.6-128.3 (6 lines), 127.9, 73.9, 64.0, 49.7, 30.0, 29.8; ^{31}P NMR (121 MHz, CDCl_3) δ -3.95; FTIR (Neat Film NaCl) 3054, 2955, 1652, 1586, 1476, 1434, 1355, 1248, 1089, 1035, 968, 742, 697 cm^{-1} ; HRMS (FAB, Pos.) m/z calc'd for $\text{C}_{26}\text{H}_{29}\text{NOP} [\text{M}+\text{H}]^+$: 402.1987, found 402.2002; $[\alpha]^{26}_{\text{D}} = -6.9$ (c 1.03, CHCl_3).




(S)-4-(2-(Benzylxy)propan-2-yl)-2-(2-(diphenylphosphino)phenyl)-4,5-dihydrooxazole. Colorless viscous oil; $R_f = 0.45$ (hexanes/EtOAc, 5/1); ^1H NMR (300 MHz, CDCl_3) δ 7.95 (ddd, $J = 7.5, 3.6, 1.2$ Hz, 1H), 7.41-7.19 (m, 17H), 6.88 (ddd, $J = 7.5, 4.2, 0.9$ Hz, 1H), 4.43-4.23 (m, 4H), 4.15 (dd, $J = 9.6, 7.8$ Hz, 1H), 1.21 (s, 3H), 0.88 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 163.8 (d, $J_{\text{CP}} = 3$ Hz), 139.5, 139.1-138.3 (5 lines), 134.4 (d, $J_{\text{CP}} = 21$ Hz), 134.2, 133.5 (d, $J_{\text{CP}} = 20$ Hz), 131.6 (d, $J_{\text{CP}} = 19$ Hz), 130.5, 129.9 (d, $J_{\text{CP}} = 3$ Hz), 128.6-128.1 (6 lines), 127.14, 127.12, 76.9, 74.9, 68.5, 63.9, 23.9, 19.5; ^{31}P NMR (121 MHz, CDCl_3) δ -5.51; FTIR (Neat Film NaCl) 3067, 2973, 2905, 1649, 1586, 1478, 1434, 1352, 1248, 1155, 1091, 1065, 1027, 964, 743, 697 cm^{-1} ; HRMS (FAB, Pos.) m/z calc'd for $\text{C}_{31}\text{H}_{31}\text{NO}_2\text{P} [\text{M}+\text{H}]_+$: 480.2092, found 480.2078; $[\alpha]^{26}_{\text{D}} = -2.0$ (c 1.03, CHCl_3).




(S)-4-(2-(tert-Butyldimethylsilyloxy)propan-2-yl)-2-(2-(diphenylphosphino)phenyl)-4,5-dihydrooxazole. White solid; mp 104-106 °C; $R_f = 0.62$ (hexanes/EtOAc, 5/1); ^1H NMR (300 MHz, CDCl_3) δ 7.92 (ddd, $J = 7.5, 3.6, 1.2$ Hz, 1H), 7.40-7.20 (m, 12H), 6.88

(ddd, $J = 7.5, 3.9, 0.9$ Hz, 1H), 4.32 (dd, $J = 7.5, 6.6$ Hz, 1H), 4.09 (dd, $J = 10.2, 7.5$ Hz, 1H), 4.02 (dd, $J = 10.2, 6.6$ Hz, 1H), 1.15 (s, 3H), 0.86 (s, 3H), 0.78 (s, 9H), 0.03 (s, 3H), 0.01 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 163.6, 139.0-138.3 (6 lines), 134.3 (d, $J_{\text{CP}} = 21$ Hz), 134.2, 133.5 (d, $J_{\text{CP}} = 20$ Hz), 131.9 (d, $J_{\text{CP}} = 19$ Hz), 130.4, 129.8 (d, $J_{\text{CP}} = 3$ Hz), 128.5-128.0 (5 lines), 76.8, 74.9, 68.7, 28.7, 25.7, 23.9, 17.9, -2.2, -2.3; ^{31}P NMR (121 MHz, CDCl_3) δ -5.99; FTIR (Neat Film NaCl) 3054, 2955, 2929, 2856, 1652, 1586, 1472, 1434, 1353, 1251, 1162, 1091, 1058, 835, 774, 743, 696 cm^{-1} ; HRMS (FAB, Pos.) m/z calc'd for $\text{C}_{30}\text{H}_{39}\text{NO}_2\text{PSi}$ [$\text{M}+\text{H}]^+$: 504.2488, found 504.2469; $[\alpha]^{26}_{\text{D}} = +19.8$ (c 1.16, CHCl_3).




(S)-2-(2-(Diphenylphosphino)phenyl)-4-(naphthalen-1-ylmethyl)-4,5-dihydrooxazole. White amorphous solid; $R_f = 0.29$ (hexanes/ Et_2O , 3/1); ^1H NMR (300 MHz, CDCl_3) δ 8.00 (m, 1H), 7.91 (m, 1H), 7.85 (m, 1H), 7.73 (d, $J = 8.4$ Hz, 1H), 7.56-7.45 (m, 2H), 7.42-7.28 (m, 13H), 7.16 (m, 1H), 6.87 (m, 1H), 4.55 (m, 1H), 3.97 (t, $J = 8.4$ Hz, 1H), 3.86 (dd, $J = 8.4, 7.2$ Hz, 1H), 3.44 (dd, $J = 14.4, 4.2$ Hz, 1H), 2.39 (dd, $J = 14.4, 10.2$ Hz, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 164.1 (d, $J_{\text{CP}} = 3$ Hz), 138.9 (d, $J_{\text{CP}} = 25$ Hz), 137.84 (d, $J_{\text{CP}} = 10$ Hz), 137.79 (d, $J_{\text{CP}} = 12$ Hz), 134.5 (d, $J_{\text{CP}} = 21$ Hz), 134.0, 133.82 (d, $J_{\text{CP}} = 21$ Hz), 133.80, 133.5 (d, $J_{\text{CP}} = 3$ Hz), 131.9, 131.3 (d, $J_{\text{CP}} = 17$ Hz), 130.6, 130.0 (d, $J_{\text{CP}} = 3$ Hz), 128.8-128.4 (6 lines), 127.9, 127.2, 126.6, 126.0, 125.6, 125.4, 123.8, 71.7, 66.7, 38.2; ^{31}P NMR (121 MHz, CDCl_3) δ -3.59; FTIR (Neat Film NaCl) 3052, 2962, 1651, 1585, 1511, 1476, 1434, 1354, 1216, 1089, 1037, 963, 745, 697 cm^{-1} ; HRMS (FAB, Pos.) m/z calc'd for $\text{C}_{33}\text{H}_{27}\text{NOP}$ [$\text{M}+\text{H}]^+$: 472.1830, found 472.1835; $[\alpha]^{24}_{\text{D}} = +29.7$ (c 0.50, CHCl_3).




(S)-2-(2-(Diphenylphosphino)phenyl)-4-(naphthalen-2-ylmethyl)-4,5-dihydrooxazole. White amorphous solid; $R_f = 0.24$ (hexanes/ Et_2O , 3/1); ^1H NMR (300 MHz, CDCl_3) δ 7.88 (m, 1H), 7.82-7.72 (m, 3H), 7.53 (br s, 1H), 7.49-7.27 (m, 14H), 7.23 (m, 1H), 6.88 (m, 1H), 4.46 (m, 1H), 4.05 (dd, $J = 9.0, 8.7$ Hz, 1H), 3.83 (dd, $J = 9.0, 7.5$ Hz, 1H), 3.08 (dd, $J = 14.1, 5.1$ Hz, 1H), 2.30 (dd, $J = 14.1, 9.3$ Hz, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 164.0 (d, $J_{\text{CP}} = 3$ Hz), 138.9 (d, $J_{\text{CP}} = 25$ Hz), 137.0-137.7 (3 lines), 135.6, 134.4 (d, $J_{\text{CP}} = 21$ Hz), 133.8 (d, $J_{\text{CP}} = 21$ Hz), 133.5 (d, $J_{\text{CP}} = 2$ Hz), 133.4, 132.1, 131.4 (d, $J_{\text{CP}} = 18$ Hz), 130.5, 129.9 (d, $J_{\text{CP}} = 3$ Hz), 128.7-127.4 (12 lines), 125.9, 125.4, 71.4, 67.7, 41.2; ^{31}P NMR (121 MHz, CDCl_3) δ -4.05; FTIR (Neat Film NaCl) 3052, 1651,


1508, 1476, 1434, 1354, 1217, 1090, 1027, 964, 817, 743, 697 cm^{-1} ; HRMS (FAB, Pos.) m/z calc'd for $\text{C}_{32}\text{H}_{27}\text{NOP}$ [M+H] $^+$: 472.1830, found 472.1845; $[\alpha]^{25}_D = +42.7$ (c 0.50, CHCl_3).




(S)-2-(2-(Diphenylphosphino)phenyl)-4-phenethyl-4,5-dihydrooxazole. Colorless viscous oil; $R_f = 0.38$ (hexanes/ Et_2O , 3/1); ^1H NMR (300 MHz, CDCl_3) δ 7.89 (ddd, $J = 7.5, 3.6, 1.5$ Hz, 1H), 7.40-7.14 (m, 15H), 7.11-7.07 (m, 2H), 6.87 (ddd, $J = 7.5, 4.2, 1.5$ Hz, 1H), 4.22 (dd, $J = 9.6, 8.1$ Hz, 1H), 4.08 (m, 1H), 3.71 (t, $J = 8.1$ Hz, 1H), 2.66-2.45 (m, 2H), 1.72-1.46 (m, 2H); ^{13}C NMR (75 MHz, CDCl_3) δ 163.0 (d, $J_{\text{CP}} = 2$ Hz), 141.8, 138.7 (d, $J_{\text{CP}} = 25$ Hz), 138.1 (d, $J_{\text{CP}} = 12$ Hz), 138.0 (d, $J_{\text{CP}} = 10$ Hz), 134.2 (d, $J_{\text{CP}} = 21$ Hz), 133.73 (d, $J_{\text{CP}} = 1$ Hz), 133.69 (d, $J_{\text{CP}} = 20$ Hz), 131.7 (d, $J_{\text{CP}} = 19$ Hz), 130.4, 129.7 (d, $J_{\text{CP}} = 3$ Hz), 128.5-128.1 (6 lines), 127.9, 125.6, 72.0, 66.3, 37.2, 32.1; ^{31}P NMR (121 MHz, CDCl_3) δ -4.55; FTIR (Neat Film NaCl) 3055, 2926, 1652, 1602, 1585, 1495, 1476, 1454, 1434, 1355, 1308, 1251, 1217, 1134, 1090, 1036, 968, 743, 696 cm^{-1} ; HRMS (FAB, Pos.) m/z calc'd for $\text{C}_{29}\text{H}_{27}\text{NOP}$ [M+H] $^+$: 436.1830, found 436.1817; $[\alpha]^{25}_D = -56.9$ (c 0.50, CHCl_3).




(S)-2-(2-(Diphenylphosphino)phenyl)-4-(2-methylbenzyl)-4,5-dihydrooxazole. Colorless viscous oil; $R_f = 0.33$ (hexanes/ Et_2O , 3/1); ^1H NMR (300 MHz, CDCl_3) δ 7.89 (m, 1H), 7.40-7.26 (m, 12H), 7.14-7.06 (m, 3H), 7.00-6.95 (m, 1H), 6.86 (m, 1H), 4.35 (m, 1H), 4.06 (t, $J = 8.4$ Hz, 1H), 3.79 (dd, $J = 8.4, 7.5$ Hz, 1H), 2.91 (dd, $J = 14.1, 5.1$ Hz, 1H), 2.26 (s, 3H), 2.10 (dd, $J = 14.1, 9.6$ Hz, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 163.8 (d, $J_{\text{CP}} = 3$ Hz), 138.9 (d, $J_{\text{CP}} = 25$ Hz), 137.9-137.7 (3 lines), 136.4, 134.4 (d, $J_{\text{CP}} = 21$ Hz), 133.8 (d, $J_{\text{CP}} = 21$ Hz), 133.5 (d, $J_{\text{CP}} = 3$ Hz), 131.4 (d, $J_{\text{CP}} = 18$ Hz), 130.5, 130.3, 129.9 (d, $J_{\text{CP}} = 3$ Hz), 129.2, 128.7-128.3 (5 lines), 127.9, 126.4, 125.9, 71.6, 66.4, 38.4, 19.6; ^{31}P NMR (121 MHz, CDCl_3) δ -3.77; FTIR (Neat Film NaCl) 3052, 1649, 1477, 1434, 1354, 1090, 1027, 964, 741, 697 cm^{-1} ; HRMS (FAB, Pos.) m/z calc'd for $\text{C}_{29}\text{H}_{27}\text{NOP}$ [M+H] $^+$: 436.1830, found 436.1798; $[\alpha]^{25}_D = +33.0$ (c 0.26, CHCl_3).




(S)-2-(2-(Diphenylphosphino)phenyl)-4-(2-(trifluoromethyl)benzyl)-4,5-dihydrooxazole. Colorless viscous oil; $R_f = 0.48$ (hexanes/EtOAc, 5/1); ^1H NMR (300 MHz, CDCl_3) δ 7.89 (ddd, $J = 7.5, 3.6, 1.2$ Hz, 1H), 7.60 (d, $J = 7.8$ Hz, 1H), 7.45-7.27 (m, 15H), 6.88 (ddd, $J = 7.5, 3.9, 1.2$ Hz, 1H), 4.39 (m, 1H), 4.19 (dd, $J = 9.3, 8.4$ Hz, 1H), 3.79 (t, $J = 8.4$ Hz, 1H), 2.89 (dd, $J = 14.7, 7.2$ Hz, 1H), 2.64 (ddd, $J = 14.7, 6.3, 0.9$ Hz, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 163.8 (d, $J_{\text{CP}} = 3$ Hz), 138.9 (d, $J_{\text{CP}} = 25$ Hz), 137.9 (d, $J_{\text{CP}} = 12$ Hz), 137.8 (d, $J_{\text{CP}} = 10$ Hz), 137.0, 134.3 (d, $J_{\text{CP}} = 21$ Hz), 133.72 (d, $J_{\text{CP}} = 20$ Hz), 133.66 (d, $J_{\text{CP}} = 2$ Hz), 131.8, 131.7, 131.5 (d, $J_{\text{CP}} = 19$ Hz), 130.6, 129.9 (d, $J_{\text{CP}} = 3$ Hz), 128.7-128.3 (6 lines), 128.0, 126.3, 125.8 (q, $J_{\text{CF}} = 6$ Hz), 124.5 (q, $J_{\text{CF}} = 273$ Hz), 71.6, 67.3, 37.5; ^{31}P NMR (121 MHz, CDCl_3) δ -4.64; ^{19}F NMR (282 MHz, CDCl_3) δ -59.76; FTIR (Neat Film NaCl) 3067, 1648, 1608, 1584, 1477, 1434, 1356, 1313, 1161, 1117, 1038, 742, 696 cm^{-1} ; HRMS (FAB, Pos.) m/z calc'd for $\text{C}_{29}\text{H}_{24}\text{F}_3\text{NOP}$ [$\text{M}+\text{H}]^+$: 490.1548, found 490.1528; $[\alpha]^{26}_{\text{D}} = -39.1$ (c 0.75, CHCl_3).




(R)-4-Benzhydryl-2-(2-(diphenylphosphino)phenyl)-4,5-dihydrooxazole. White amorphous solid; $R_f = 0.45$ (hexanes/EtOAc, 5/1); ^1H NMR (300 MHz, CDCl_3) δ 7.79 (m, 1H), 7.38-7.13 (m, 22H), 6.88 (m, 1H), 4.92 (q, $J = 9.0$ Hz, 1H), 4.13 (dd, $J = 9.3, 9.0$ Hz, 1H), 3.79 (t, $J = 9.0$ Hz, 1H), 3.72 (d, $J = 9.0$ Hz, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 164.2, 142.2, 142.1, 138.8 (d, $J_{\text{CP}} = 25$ Hz), 138.0-137.7 (3 lines), 134.1 (d, $J_{\text{CP}} = 21$ Hz), 133.9 (d, $J_{\text{CP}} = 21$ Hz), 133.7 (d, $J_{\text{CP}} = 2$ Hz), 131.7 (d, $J_{\text{CP}} = 19$ Hz), 130.5, 130.0 (d, $J_{\text{CP}} = 3$ Hz), 128.7-128.2 (9 lines), 128.0, 126.5, 126.2, 71.1, 70.1, 56.1; ^{31}P NMR (121 MHz, CDCl_3) δ -5.22; FTIR (Neat Film NaCl) 3056, 3026, 2895, 1649, 1598, 1584, 1494, 1477, 1451, 1434, 1356, 1091, 1029, 909, 741 cm^{-1} ; HRMS (FAB, Pos.) m/z calc'd for $\text{C}_{34}\text{H}_{29}\text{NOP}$ [$\text{M}+\text{H}]^+$: 498.1987, found 498.1963; $[\alpha]^{24}_{\text{D}} = +10.4$ (c 1.00, CHCl_3).




(R)-4-(3,5-Di-*tert*-butylbenzyl)-2-(diphenylphosphino)phenyl-4,5-dihydrooxazole. Colorless viscous oil; $R_f = 0.52$ (hexanes/EtOAc, 5/1); ^1H NMR (300 MHz, CDCl₃) δ 7.89 (m, 1H), 7.40-7.28 (m, 13H), 6.92 (d, $J = 1.8$ Hz, 2H), 6.86 (m, 1H), 4.33 (m, 1H), 4.00 (t, $J = 8.7$ Hz, 1H), 3.78 (dd, $J = 8.7, 7.5$ Hz, 1H), 2.95 (dd, $J = 13.8, 4.2$ Hz, 1H), 2.01 (dd, $J = 13.8, 10.2$ Hz, 1H), 1.30 (s, 18H); ^{13}C NMR (75 MHz, CDCl₃) δ 163.9 (d, $J_{\text{CP}} = 3$ Hz), 150.8, 138.9 (d, $J_{\text{CP}} = 25$ Hz), 137.9 (d, $J_{\text{CP}} = 12$ Hz), 137.8 (d, $J_{\text{CP}} = 10$ Hz), 137.2, 134.4 (d, $J_{\text{CP}} = 21$ Hz), 134.0 (d, $J_{\text{CP}} = 21$ Hz), 133.4 (d, $J_{\text{CP}} = 3$ Hz), 131.5 (d, $J_{\text{CP}} = 17$ Hz), 130.5, 130.0 (d, $J_{\text{CP}} = 3$ Hz), 128.8-128.4 (6 lines), 127.9, 123.3, 120.3, 71.6, 68.1, 41.6, 34.7, 31.5; ^{31}P NMR (121 MHz, CDCl₃) δ -3.60; FTIR (Neat Film NaCl) 2963, 1649, 1598, 1477, 1434, 1361, 1248, 1090, 1027, 965, 742, 696 cm⁻¹; HRMS (FAB, Pos.) m/z calc'd for C₃₆H₄₁NOP [M+H]⁺: 534.2926, found 534.2905; $[\alpha]^{25}_{\text{D}} = -49.3$ (c 0.36, CHCl₃).




(S)-4-(Benzo[*b*]thiophen-3-ylmethyl)-2-(diphenylphosphino)phenyl-4,5-dihydrooxazole. White amorphous solid; $R_f = 0.38$ (hexanes/EtOAc, 5/1); ^1H NMR (300 MHz, CDCl₃) δ 7.89 (m, 1H), 7.85 (m, 1H), 7.69 (m, 1H), 7.42-7.28 (m, 14H), 7.01 (s, 1H), 6.88 (m, 1H), 4.54 (m, 1H), 4.14 (t, $J = 8.4$ Hz, 1H), 3.83 (dd, $J = 8.4, 7.5$ Hz, 1H), 3.03 (ddd, $J = 14.7, 5.4, 1.2$ Hz, 1H), 2.40 (dd, $J = 14.7, 9.0$ Hz, 1H); ^{13}C NMR (75 MHz, CDCl₃) δ 163.8 (d, $J_{\text{CP}} = 3$ Hz), 140.2, 139.0-138.7 (3 lines), 137.9-137.8 (3 lines), 134.4 (d, $J_{\text{CP}} = 21$ Hz), 133.7 (d, $J_{\text{CP}} = 21$ Hz), 133.6 (d, $J_{\text{CP}} = 2$ Hz), 132.6, 131.3 (d, $J_{\text{CP}} = 18$ Hz), 130.5, 129.9 (d, $J_{\text{CP}} = 2$ Hz), 128.7-128.3 (6 lines), 127.9, 124.2, 123.8, 122.7, 122.6, 121.5, 71.7, 66.0, 33.9; ^{31}P NMR (121 MHz, CDCl₃) δ -4.21; FTIR (Neat Film NaCl) 3054, 2963, 1651, 1585, 1476, 1434, 1356, 1252, 1216, 1090, 1026, 965, 749, 697 cm⁻¹; HRMS (FAB, Pos.) m/z calc'd for C₃₀H₂₅NOPS [M+H]⁺: 478.1394, found 478.1416; $[\alpha]^{26}_{\text{D}} = +30.1$ (c 1.00, CHCl₃).




(S)-4-((1*H*-Indol-3-yl)methyl)-2-(diphenylphosphino)phenyl-4,5-dihydrooxazole.⁶




(S)-4-*tert*-Butyl-2-(2-(di-*p*-tolylphosphino)phenyl)-4,5-dihydrooxazole. Colorless viscous oil; $R_f = 0.39$ (hexanes/EtOAc, 9/1); ^1H NMR (300 MHz, CDCl_3) δ 7.91 (ddd, $J = 7.5, 3.6, 1.5$ Hz, 1H), 7.33 (m, 1H), 7.26 (m, 1H), 7.23-7.05 (m, 8H), 6.89 (ddd, $J = 7.5, 4.2, 1.5$ Hz, 1H), 4.06 (dd, $J = 10.2, 8.4$ Hz, 1H), 3.98 (t, $J = 8.3$ Hz, 1H), 3.85 (dd, $J = 10.2, 7.8$ Hz, 1H), 2.33 (s, 3H), 2.32 (s, 3H), 0.75 (s, 9H); ^{13}C NMR (75 MHz, CDCl_3) δ 163.0 (d, $J_{\text{CP}} = 3$ Hz), 139.3 (d, $J_{\text{CP}} = 25$ Hz), 138.4, 138.1, 135.0-134.7 (4 lines), 134.3 (d, $J_{\text{CP}} = 21$ Hz), 133.9, 133.6 (d, $J_{\text{CP}} = 20$ Hz), 131.9 (d, $J_{\text{CP}} = 20$ Hz), 130.2, 129.9 (d, $J_{\text{CP}} = 3$ Hz), 129.2 (d, $J_{\text{CP}} = 7$ Hz), 129.0 (d, $J_{\text{CP}} = 7$ Hz), 127.8, 76.5, 68.3, 33.6, 25.7, 21.3, 21.2; ^{31}P NMR (121 MHz, CDCl_3) δ -6.98; FTIR (Neat Film NaCl) 2953, 1653, 1496, 1476, 1394, 1353, 1306, 1248, 1185, 1134, 1089, 1024, 967, 805, 743 cm^{-1} ; HRMS (EI) m/z calc'd for $\text{C}_{27}\text{H}_{30}\text{NOP}$ [M^+]: 415.2065, found 415.2065; $[\alpha]^{25}_{\text{D}} = -58.8$ (c 2.23, CHCl_3).




(S)-2-(2-(Bis(4-(trifluoromethyl)phenyl)phosphino)phenyl)-4-*tert*-butyl-4,5-dihydrooxazole. White amorphous powder; $R_f = 0.44$ (hexanes/EtOAc, 9/1); ^1H NMR (300 MHz, CDCl_3) δ 8.00 (ddd, $J = 7.5, 3.9, 1.2$ Hz, 1H), 7.62-7.50 (m, 4H), 7.44 (m, 1H), 7.40-7.28 (m, 5H), 6.82 (ddd, $J = 7.5, 3.9, 0.9$ Hz, 1H), 4.20 (dd, $J = 10.2, 8.4$ Hz, 1H), 4.06 (t, $J = 8.4$ Hz, 1H), 3.93 (dd, $J = 10.2, 8.4$ Hz, 1H), 0.69 (s, 9H); ^{13}C NMR (75 MHz, CDCl_3) δ 161.8 (d, $J_{\text{CP}} = 3$ Hz), 143.4-143.2 (m), 136.7 (d, $J_{\text{CP}} = 24$ Hz), 134.4 (d, $J_{\text{CP}} = 21$ Hz), 134.2, 133.7 (d, $J_{\text{CP}} = 20$ Hz), 132.0 (d, $J_{\text{CP}} = 20$ Hz), 130.74, 130.65 (q, $J_{\text{CF}} = 32$ Hz), 130.5 (q, $J_{\text{CF}} = 32$ Hz), 129.9 (d, $J_{\text{CP}} = 3$ Hz), 128.9, 125.3-124.9 (m), 124.1 (q, $J_{\text{CF}} = 271$ Hz), 77.0, 68.4, 33.6, 25.6; ^{31}P NMR (121 MHz, CDCl_3) δ -7.29; ^{19}F NMR (282 MHz, CDCl_3) δ -63.23, -63.28; FTIR (Neat Film NaCl) 2958, 1653, 1606, 1480, 1396, 1324, 1166, 1128, 1106, 1061, 1017, 831, 700 cm^{-1} ; HRMS (EI) m/z calc'd for $\text{C}_{27}\text{H}_{24}\text{NOPF}_6$ [M^+]: 523.1500, found 523.1494; $[\alpha]^{25}_{\text{D}} = -21.1$ (c 2.26, CHCl_3).

**(S)-4-*tert*-Butyl-2-(2-(diphenylphosphino)-5-methoxyphenyl)-4,5-dihydrooxazole.**

White amorphous powder; $R_f = 0.61$ (hexanes/EtOAc, 3/1); ^1H NMR (300 MHz, CDCl_3) δ 7.48 (t, $J = 2.9$ Hz, 1H), 7.34-7.18 (m, 10H), 6.84 (ddd, $J = 8.7, 2.4, 0.6$ Hz, 1H), 6.78 (ddd, $J = 8.7, 3.3, 0.6$ Hz, 1H), 4.13 (dd, $J = 10.2, 8.4$ Hz, 1H), 4.03 (t, $J = 8.1$ Hz, 1H), 3.92 (dd, $J = 10.2, 8.1$ Hz, 1H), 3.82 (s, 3H), 0.73 (s, 9H); ^{13}C NMR (75 MHz, CDCl_3) δ 162.5 (d, $J_{\text{CP}} = 3$ Hz), 159.4, 139.0 (d, $J_{\text{CP}} = 13$ Hz), 138.7 (d, $J_{\text{CP}} = 10$ Hz), 135.8, 134.1 (d, $J_{\text{CP}} = 20$ Hz), 133.41 (d, $J_{\text{CP}} = 33$ Hz), 133.36 (d, $J_{\text{CP}} = 20$ Hz), 129.3 (d, $J_{\text{CP}} = 22$ Hz), 128.3-128.0 (6 lines), 116.5, 114.9 (d, $J_{\text{CP}} = 4$ Hz), 76.7, 68.3, 55.3, 33.6, 25.7; ^{31}P NMR (121 MHz, CDCl_3) δ -10.12; FTIR (Neat Film NaCl) 3069, 2956, 2903, 1654, 1594, 1561, 1479, 1434, 1354, 1336, 1297, 1224, 1181, 1093, 1050, 1022, 973, 744, 697 cm^{-1} ; HRMS (EI) m/z calc'd for $\text{C}_{26}\text{H}_{28}\text{NO}_2\text{P} [\text{M}^+]$: 417.1858, found 417.1844; $[\alpha]^{25}_D = -48.8$ (c 2.11, CHCl_3).


**(S)-2-(2-(Bis(4-(trifluoromethyl)phenyl)phosphino)-5-methoxyphenyl)-4-*tert*-butyl-4,5-dihydrooxazole.**

White amorphous powder; $R_f = 0.43$ (hexanes/EtOAc, 9/1); ^1H NMR (300 MHz, CDCl_3) δ 7.60-7.50 (m, 5H), 7.40-7.26 (m, 4H), 6.89 (dd, $J = 8.4, 3.0$ Hz, 1H), 6.74 (dd, $J = 8.4, 3.6$ Hz, 1H), 4.23 (dd, $J = 10.2, 8.4$ Hz, 1H), 4.08 (t, $J = 8.4$ Hz, 1H), 3.96 (dd, $J = 10.2, 8.4$ Hz, 1H), 3.85 (s, 3H), 0.69 (s, 9H); ^{13}C NMR (75 MHz, CDCl_3) δ 161.7 (d, $J_{\text{CP}} = 3$ Hz), 160.0, 143.9-143.6 (3 lines), 135.9, 134.2 (d, $J_{\text{CP}} = 21$ Hz), 133.6 (d, $J_{\text{CP}} = 21$ Hz), 130.5 (q, $J_{\text{CF}} = 32$ Hz), 130.3 (q, $J_{\text{CF}} = 32$ Hz), 127.1 (d, $J_{\text{CP}} = 21$ Hz), 125.2-124.8 (7 lines), 124.1 (q, $J_{\text{CF}} = 270$ Hz), 116.7, 115.1 (d, $J_{\text{CP}} = 4$ Hz), 77.0 (d, $J_{\text{CP}} = 1$ Hz), 68.4, 55.4, 33.6, 25.6; ^{31}P NMR (121 MHz, CDCl_3) δ -13.06; ^{19}F NMR (282 MHz, CDCl_3) δ -63.20, -63.24; FTIR (Neat Film NaCl) 2959, 2870, 1652, 1595, 1563, 1485, 1396, 1322, 1226, 1166, 1127, 1106, 1061, 1017, 973, 909, 832, 735, 700 cm^{-1} ; HRMS (FAB, Pos) m/z calc'd for $\text{C}_{28}\text{H}_{27}\text{F}_6\text{NO}_2\text{P} [\text{M}+\text{H}]^+$: 554.1683, found 554.1659; $[\alpha]^{24}_D = -24.5$ (c 2.61, CHCl_3).




(S)-4-tert-Butyl-2-(2-(diphenylphosphino)-5-(trifluoromethyl)phenyl)-4,5-dihydrooxazole.

White powder; mp 98–100 °C; R_f = 0.45 (hexanes/EtOAc, 9/1); ^1H NMR (300 MHz, CDCl_3) δ 8.20 (m, 1H), 7.51 (dd, J = 8.1, 1.8 Hz, 1H), 7.38–7.18 (m, 10H), 6.99 (dd, J = 8.1, 3.3 Hz, 1H), 4.12 (dd, J = 10.2, 8.4 Hz, 1H), 4.03 (t, J = 8.4 Hz, 1H), 3.90 (dd, J = 10.2, 8.4 Hz, 1H), 0.72 (s, 9H); ^{13}C NMR (75 MHz, CDCl_3) δ 161.4 (d, $J_{\text{CP}} = 3$ Hz), 144.2 (d, $J_{\text{CP}} = 30$ Hz), 137.7 (d, $J_{\text{CP}} = 12$ Hz), 137.3 (d, $J_{\text{CP}} = 9$ Hz), 134.6, 134.3 (d, $J_{\text{CP}} = 21$ Hz), 133.6 (d, $J_{\text{CP}} = 20$ Hz), 132.2 (d, $J_{\text{CP}} = 19$ Hz), 130.1 (q, $J_{\text{CF}} = 33$ Hz), 128.9–128.4 (6 lines), 126.6–126.3 (m), 123.7 (q, $J_{\text{CF}} = 271$ Hz), 77.0 (d, $J_{\text{CP}} = 1$ Hz), 68.4, 33.6, 25.7; ^{31}P NMR (121 MHz, CDCl_3) δ -6.55 ($J_{\text{PF}} = 2$ Hz); ^{19}F NMR (282 MHz, CDCl_3) δ -63.36; FTIR (Neat Film NaCl) 3071, 2957, 1655, 1478, 1434, 1407, 1357, 1343, 1326, 1302, 1262, 1244, 1174, 1131, 1080, 969, 744, 696 cm^{-1} ; HRMS (EI) m/z calc'd for $\text{C}_{26}\text{H}_{25}\text{NOPF}_3$ [M^+]: 455.1626, found 455.1646; $[\alpha]^{25}_{\text{D}} = -36.3$ (c 2.39, CHCl_3).



(S)-2-(2-(Bis(4-(trifluoromethyl)phenyl)phosphino)-5-(trifluoromethyl)phenyl)-4-tert-butyl-4,5-dihydrooxazole.


White amorphous powder; R_f = 0.63 (hexanes/EtOAc, 9/1); ^1H NMR (300 MHz, CDCl_3) δ 8.26 (m, 1H), 7.64–7.54 (m, 5H), 7.39–7.27 (m, 4H), 6.95 (dd, J = 7.8, 3.0 Hz, 1H), 4.25 (dd, J = 10.2, 8.7 Hz, 1H), 4.09 (t, J = 8.7 Hz, 1H), 3.95 (dd, J = 10.2, 8.7 Hz, 1H), 0.69 (s, 9H); ^{13}C NMR (75 MHz, CDCl_3) δ 160.7 (d, $J_{\text{CP}} = 4$ Hz), 142.6–141.7 (6 lines), 134.7–133.6 (5 lines), 132.4 (d, $J_{\text{CP}} = 20$ Hz), 131.1 (q, $J_{\text{CF}} = 32$ Hz), 130.9 (q, $J_{\text{CF}} = 32$ Hz), 127.0 (q, $J_{\text{CF}} = 3$ Hz), 126.7–126.4 (6 lines), 125.6–125.1 (8 lines), 123.9 (q, $J_{\text{CF}} = 271$ Hz), 123.5 (q, $J_{\text{CF}} = 271$ Hz), 77.3 (d, $J_{\text{CP}} = 1$ Hz), 68.6, 33.5, 25.6; ^{31}P NMR (121 MHz, CDCl_3) δ -6.57; ^{19}F NMR (282 MHz, CDCl_3) δ -63.33, -63.39, -63.53; FTIR (Neat Film NaCl) 2960, 1657, 1606, 1479, 1397, 1324, 1169, 1129, 1107, 1082, 1061, 1017, 832, 700 cm^{-1} ; HRMS (FAB, Pos) m/z calc'd for $\text{C}_{28}\text{H}_{24}\text{F}_9\text{NOP}$ [$\text{M}+\text{H}]^+$: 592.1452, found 592.1480; $[\alpha]^{24}_{\text{D}} = -16.0$ (c 2.56, CHCl_3).



[Cy₂PH₂]BF₄.⁷ To a cooled (0 °C) solution of Cy₂PH (0.700 mL, 3.46 mmol, 1.00 equiv) in Et₂O (10 mL) was added HBF₄ (54 wt% in Et₂O, 0.386 mL, 5.19 mmol, 1.50 equiv) in a dropwise fashion over 1 min. During the addition, a white precipitate was formed. After this, the ice-bath was removed and the reaction mixture was stirred for 15 min at ambient temperature. The resulting precipitate was collected by filtration, washed with dry Et₂O (2 x 10 mL) and dried under vacuum to afford [Cy₂PH₂]BF₄ (755 mg, 2.63 mmol, 76% yield) as a white powder; mp 275 °C (dec.); ¹H NMR (300 MHz, CDCl₃) δ 5.89 (dm, J_{HP} = 482 Hz, 2H), 2.65 (m, 2H), 2.09 (m, 4H), 1.87 (m, 4H), 1.76 (m, 2H), 1.68-1.20 (m, 10H); ¹³C NMR (75 MHz, CDCl₃) δ 27.9 (d, J_{CP} = 3.4 Hz), 25.8 (d, J_{CP} = 42 Hz), 25.7 (d, J_{CP} = 14 Hz), 24.8 (d, J_{CP} = 1.4 Hz); ³¹P NMR (121 MHz, CDCl₃) δ -0.37; FTIR (KBr) 2932, 2858, 2231, 1452, 1061 cm⁻¹.

[i-Bu₂PH₂]BF₄. Prepared in an analogous manner to the previous entry. White powder; mp 280 °C (dec.); ¹H NMR (300 MHz, CD₃CN) δ 5.98 (dm, J_{HP} = 496 Hz, 2H), 2.30-2.15 (m, 4H), 2.07 (m, 2H), 1.07 (dd, J_{HH} = 6.6 Hz, J_{HP} = 1.5 Hz, 12H); ¹³C NMR (75 MHz, CD₃CN) δ 25.8 (d, J_{CP} = 4.8 Hz), 23.5 (d, J_{CP} = 46 Hz), 23.2 (d, J_{CP} = 11 Hz); ³¹P NMR (121 MHz, CD₃CN) δ -27.4; FTIR (KBr) 2965, 1471, 1393, 1084 cm⁻¹.

General Procedure for the Copper Catalyzed Synthesis of PHOX Ligands Utilizing a Dialkylphosphonium Salt



(S)-4-tert-Butyl-2-(2-(dicyclohexylphosphino)phenyl)-4,5-dihydrooxazole, borane complex (SI3). A flame-dried 50 mL Schlenk tube containing stir bar was evacuated and refilled with dry nitrogen and then charged with [Cy₂PH₂]BF₄ (538 mg, 1.88 mmol, 1.88 equiv), anhydrous toluene (4.0 mL) followed by Cs₂CO₃ (1630 mg, 5.00 mmol, 5.00 equiv). After 10 min of stirring, CuI (23.8 mg, 0.125 mmol, 0.125 eq.) and *N,N'*-dimethylethylenediamine (93 μ L, 0.875 mmol, 0.875 eq.) were added to the mixture and the resulting suspension was stirred for 10 min. To this was added **SI2** (282 mg, 1.00 mmol, 1.0 eq.) and toluene (4.0 mL) and the Schlenk tube was sealed and the reaction mixture was stirred at 110°C until the complete consumption of the aryl bromide (27 h). The resulting reaction mixture was allowed to cool to 0 °C, BH₃-THF complex (1.0 M in THF, 3.0 mL, 3.00 mmol, 3.00 eq.) was slowly add to this mixture. After 2 h stirring at ambient temperature, the reaction was quenched by the addition of 20 mL of water and extracted with ether (20 mL x 2). The combined organic layers were washed with brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residual crude

oil was purified by flash SiO₂ column (hexanes/EtOAc, 40/1) to afford 259 mg (63% yield) of desired borane complex **SI3** as a white solid; mp 143-145 °C; R_f = 0.52 (hexanes/Et₂O, 5/1); ¹H NMR (300 MHz, CDCl₃) δ 8.18 (m, 1H), 7.78 (m, 1H), 7.54-7.46 (m, 2H), 4.41 (dd, J = 9.9, 8.1 Hz, 1H), 4.21 (dd, J = 9.9, 8.1 Hz, 1H), 4.10 (t, J = 9.9 Hz, 1H), 2.83 (m, 1H), 2.57 (m, 1H), 1.98-1.74 (m, 4H), 1.74-1.55 (m, 6H), 1.32-1.10 (m, 10H), 1.02 (s, 9H), 1.00-0.00 (br., 3H); ¹³C NMR (75 MHz, CDCl₃) δ 163.1 (d, J_{CP} = 2 Hz), 138.2 (d, J_{CP} = 15 Hz), 132.0, 130.7-130.2 (6 lines), 127.3 (d, J_{CP} = 43 Hz), 77.3, 68.6, 33.7, 33.6 (d, J_{CP} = 32 Hz), 33.5 (d, J_{CP} = 32 Hz), 28.64, 28.55, 27.84, 27.78, 27.3 (d, J_{CP} = 6 Hz), 27.1 (d, J_{CP} = 6 Hz), 27.0, 26.9, 26.2, 25.78, 25.76; ³¹P NMR (121 MHz, CDCl₃) δ 38.22 (br d); FTIR (Neat Film NaCl) 2930, 2852, 2363, 2344, 1653, 1477, 1448, 1364, 1332, 1305, 1246, 1100, 1063, 1037, 962, 760 cm⁻¹; HRMS (EI) *m/z* calc'd for C₂₅H₄₀BNOP [M-H]⁺: 412.2941, found 412.2971; [α]_D²⁴ = -5.6 (*c* 1.71, CHCl₃).

The phosphine-borane complex **SI3** was recrystallized from hexanes to provide crystals suitable for X-ray analysis.




Figure 1. ORTEP drawing of **SI3**

Note: Crystallographic data have been deposited at the CCDC, 12 Union Road, Cambridge CB2 1EZ, UK and copies can be obtained on request, free of charge, by quoting the publication citation and the deposition number 292036.

Table 1. Crystal data and structure refinement for SI3 (CCDC 292036).

Empirical formula	C ₂₅ H ₄₁ BNOP
Formula weight	413.37
Crystallization Solvent	Hexanes
Crystal Habit	Blade
Crystal size	0.33 x 0.30 x 0.12 mm ³
Crystal color	Colorless

Data Collection

Type of diffractometer	Bruker SMART 1000
Wavelength	0.71073 Å MoKα
Data Collection Temperature	100(2) K
θ range for 20368 reflections used in lattice determination	2.13 to 27.97°
Unit cell dimensions	a = 10.5651(5) Å b = 19.0701(10) Å c = 24.3655(12) Å
	α = 88.9530(10)° β = 87.6200(10)° γ = 85.2710(10)°
Volume	4887.6(4) Å ³
Z	8
Crystal system	Triclinic
Space group	P1
Density (calculated)	1.124 Mg/m ³
F(000)	1808
Data collection program	Bruker SMART v5.630
θ range for data collection	1.67 to 28.47°
Completeness to θ = 28.47°	90.0 %
Index ranges	-13 ≤ h ≤ 14, -24 ≤ k ≤ 25, -31 ≤ l ≤ 31
Data collection scan type	ω scans at 5 φ settings
Data reduction program	Bruker SAINT v6.45A
Reflections collected	72958
Independent reflections	43112 [R _{int} = 0.0534]
Absorption coefficient	0.128 mm ⁻¹
Absorption correction	None
Max. and min. transmission	0.9848 and 0.9590

Table 1 (cont.)**Structure solution and Refinement**


Structure solution program	Bruker XS v6.12
Primary solution method	Direct methods
Secondary solution method	Difference Fourier map
Hydrogen placement	Geometric positions
Structure refinement program	Bruker XL v6.12
Refinement method	Full matrix least-squares on F^2
Data / restraints / parameters	43112 / 3 / 2121
Treatment of hydrogen atoms	Riding
Goodness-of-fit on F^2	1.001
Final R indices [$I > 2\sigma(I)$, 26848 reflections]	$R_1 = 0.0512, wR_2 = 0.0789$
R indices (all data)	$R_1 = 0.0963, wR_2 = 0.0881$
Type of weighting scheme used	Sigma
Weighting scheme used	$w = 1/\sigma^2(F_{\text{o}}^2)$
Max shift/error	0.001
Average shift/error	0.000
Absolute structure parameter	-0.04(5)
Largest diff. peak and hole	0.424 and -0.360 e. \AA^{-3}

Special Refinement Details

This crystal has eight molecules in the unit cell, each of them distinct with respect to the torsion angles within the (4-*tert*-butyl-1,3-oxazolin-2-yl)phenyl ligand. These conformational difference are propagated to the cyclohexyl ligands as well. An interesting feature in this figure is the fan-like positions of the eight oxygen atoms relative the more-or-less centralized position of the eight nitrogen atoms.


Refinement of F^2 against ALL reflections. The weighted R-factor (wR) and goodness of fit (S) are based on F^2 , conventional R-factors (R) are based on F, with F set to zero for negative F^2 . The threshold expression of $F^2 > 2\sigma(F^2)$ is used only for calculating R-factors (gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based on F^2 are statistically about twice as large as those based on F, and R-factors based on ALL data will be even larger.

All esds (except the esd in the dihedral angle between two l.s. planes) are estimated using the full covariance matrix. The cell esds are taken into account individually in the estimation of esds in distances, angles and torsion angles; correlations between esds in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell esds is used for estimating esds involving l.s. planes.




(S)-4-tert-Butyl-2-(2-(diisobutylphosphino)phenyl)-4,5-dihydrooxazole, borane complex. Prepared in an analogous manner to the previous entry. White powder; $R_f = 0.46$ (hexanes/Et₂O, 5/1); mp 44-46 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.28 (m, 1H), 7.85 (m, 1H), 7.57-7.48 (m, 2H), 4.39 (dd, $J = 9.6, 8.4$ Hz, 1H), 4.21 (dd, $J = 9.6, 8.4$ Hz, 1H), 4.10 (t, $J = 9.6$ Hz, 1H), 2.59 (m, 1H), 2.26 (m, 1H), 2.08-1.70 (m, 4H), 2.00-0.00 (br, 3H), 1.00 (s, 9H), 0.97 (d, $J = 6.9$ Hz, 3H), 0.94 (d, $J = 6.9$ Hz, 3H), 0.71 (d, $J = 6.6$ Hz, 6H); ¹³C NMR (75 MHz, CDCl₃) δ 162.8 (d, $J_{CP} = 2$ Hz), 137.8 (d, $J_{CP} = 18$ Hz), 132.0, 130.95 (d, $J_{CP} = 3$ Hz), 130.90, 130.6 (d, $J_{CP} = 13$ Hz), 128.7 (d, $J_{CP} = 41$ Hz), 77.2, 68.5, 35.4 (d, $J_{CP} = 35$ Hz), 34.5 (d, $J_{CP} = 35$ Hz), 33.9, 26.1, 24.9 (d, $J_{CP} = 7$ Hz), 24.8 (d, $J_{CP} = 6$ Hz), 24.6, 24.3 (d, $J_{CP} = 7$ Hz), 24.1 (d, $J_{CP} = 7$ Hz); ³¹P NMR (121 MHz, CDCl₃) δ 18.77 (br d); FTIR (Neat film, NaCl) 2957, 2870, 2381, 1661, 1588, 1568, 1466, 1366, 1335, 1247, 1103, 1064, 1038, 1025, 963, 819, 773, 735 cm⁻¹; HRMS (EI) *m/z* calc'd for C₂₁H₃₆BNOP [M-H]⁺: 360.2628, found 360.2623; [α]_D²⁵ = +8.9 (*c* 1.00, CHCl₃).

General Procedure for the Deprotection of PHOX-Borane Complexes.⁸



(S)-4-tert-Butyl-2-(2-(dicyclohexylphosphino)phenyl)-4,5-dihydrooxazole (SI4).⁹ Molecular sieves 4 Å (MS4 Å) were heated to 180 °C under vacuum for 24 h prior to use. A Schlenk tube equipped with a stir bar was flame-dried under vacuum and backfilled with dry nitrogen. The Schlenk tube was charged with the phosphine-borane complex **SI3** (40.0 mg, 0.0968 mmol), MS4 Å (160 mg), THF (2 mL) and MeOH (1 mL). The mixture was stirred at 70 °C for 72 h. After cooling, the resulting mixture was filtered through a plug of Celite under nitrogen and concentrated in vacuo. The resulting residue was dissolved in ether, passed through a plug of silica gel under nitrogen and concentrated in vacuo to afford desired phosphine **SI4** (36.8 mg, 0.0921 mmol, 95% yield) as a colorless oil, without further purification; $R_f = 0.33$ (hexanes/Et₂O, 5/1); ¹H NMR (300 MHz, CDCl₃) δ 7.62 (m, 1H), 7.52 (m, 1H), 7.42-7.28 (m, 2H), 4.37 (dd, $J = 10.2, 8.1$ Hz, 1H), 4.21 (t, $J = 8.1$ Hz, 1H), 4.08 (dd, $J = 10.2, 8.1$ Hz, 1H), 1.96-1.46 (m, 12H), 1.34-1.04 (m, 10H), 0.98 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 165.0 (d, $J_{CP} = 2$ Hz), 136.8 (d, $J_{CP} = 29$ Hz), 136.7 (d, $J_{CP} = 26$ Hz), 132.6 (d, $J_{CP} = 3$ Hz), 129.7 (d, $J_{CP} = 7$ Hz), 129.1, 128.2, 76.6, 68.7, 34.7 (d, $J_{CP} = 14$ Hz), 34.4 (d, $J_{CP} = 14$ Hz), 34.0, 30.2-29.8 (6 lines), 27.3-27.1 (6 lines), 26.40, 26.37, 26.2; ³¹P NMR (121 MHz, CDCl₃) δ -4.92; FTIR (Neat film, NaCl) 2925, 2850, 1658, 1478, 1446, 1351, 1240, 1091, 1024, 966 cm⁻¹;

HRMS (FAB, Pos.) m/z calc'd for $C_{25}H_{39}NOP$ [M+H]⁺: 400.2769, found 400.2754; $[\alpha]^{24}_D = -34.5$ (*c* 0.50, CHCl₃).



(S)-4-tert-Butyl-2-(2-(diisobutylphosphino)phenyl)-4,5-dihydrooxazole. Prepared in an analogous manner to the previous entry. Colorless oil; $R_f = 0.37$ (hexanes/Et₂O, 5/1); ¹H NMR (300 MHz, CDCl₃) δ 7.65–7.53 (m, 2H), 7.42 (m, 1H), 7.33 (m, 1H), 4.39 (dd, *J* = 10.2, 8.4 Hz, 1H), 4.24 (t, *J* = 8.4 Hz, 1H), 4.09 (dd, *J* = 10.2, 8.4 Hz, 1H), 1.85–1.40 (m, 6H), 1.00 (s, 9H), 0.96 (dd, *J_{HH}* = 6.6 Hz, *J_{HP}* = 2.4 Hz, 6H), 0.92 (dd, *J_{HH}* = 6.3 Hz, *J_{HP}* = 3.6 Hz, 6H); ¹³C NMR (75 MHz, CDCl₃) δ 165.0 (d, *J_{CP}* = 1 Hz), 140.5 (d, *J_{CP}* = 25 Hz), 135.5 (d, *J_{CP}* = 30 Hz), 130.6 (d, *J_{CP}* = 3 Hz), 129.9, 129.3 (d, *J_{CP}* = 6 Hz), 128.2, 76.7, 68.7, 40.1 (d, *J_{CP}* = 14 Hz), 39.9 (d, *J_{CP}* = 14 Hz), 33.9, 26.32 (d, *J_{CP}* = 13 Hz), 26.27 (d, *J_{CP}* = 13 Hz), 26.1, 24.51 (d, *J_{CP}* = 9 Hz), 24.46 (d, *J_{CP}* = 8 Hz), 24.14 (d, *J_{CP}* = 9 Hz), 24.06 (d, *J_{CP}* = 9 Hz); ³¹P NMR (121 MHz, CDCl₃) δ -38.92; FTIR (Neat film, NaCl) 2953, 2868, 1660, 1464, 1364, 1351, 1335, 1243, 1093, 1048, 967 cm⁻¹; HRMS (FAB, Pos.) m/z calc'd for $C_{21}H_{35}NOP$ [M+H]⁺: 348.2456, found 348.2445; $[\alpha]^{24}_D = -40.7$ (*c* 0.52, CHCl₃).

References:

1. Busacca, C. A.; Lorenz, J. C.; Grinberg, N.; Haddad, N.; Hrapchak, M.; Latli, B.; Lee, H.; Sabilia, P.; Saha, A.; Sarvestani, M.; Shen, S.; Varsolona, R.; Wei, X.; Senanayake, C. H. *Org. Lett.* **2005**, 7, 4277–4280.
2. McKennon, M. J.; Meyers, A. I.; Drauz, K.; Schwarm, M. *J. Org. Chem.* **1993**, 58, 3568–3571.
3. 2-Bromo-5-methoxybenzoic acid was purchased from Sigma-Aldrich Chemical Company. 2-Bromo-5-(tri-fluoromethyl)benzoic acid was synthesized by the known method, see: Mongin, F.; Desponds, O.; Schlosser, M. *Tetrahedron Lett.* **1996**, 37, 2767–2770.
4. Zhou, Q. L.; Pfaltz, A. *Tetrahedron Lett.* **1993**, 34, 7725–7728.
5. Koch, G.; Lloyd-Jones, G. C.; Loiseleur, O.; Pfaltz, A.; Prêtôt, R.; Schaffner, S.; Schnider, P.; Matt, P. *Recl. Trav. Chim. Pays-Bas.* **1995**, 114, 206–210.
6. Peer, M.; de Jong, J. C.; Kiefer, M.; Langer, T.; Rieck, H.; Schell, H.; Sennhenn, P.; Sprinz, J.; Steinhagen, H.; Wiese, B.; Helmchen, G. *Tetrahedron* **1996**, 52, 7547–7583.

7. The preparation of $[t\text{-Bu}_2\text{PH}_2]\text{BF}_4$ has been reported, see: Stefanescu, D. M.; Yuen, H. F.; Glueck, D. S.; Golen, J. A.; Zakharov, L. N.; Incarvito, C. D.; Rheingold, A. L. *Inorg. Chem.* **2003**, *42*, 8891-8901.
8. Schröder, M.; Nozaki, K.; Hiyama, T. *Bull. Chem. Soc. Jpn.* **2004**, *77*, 1931-1932.
9. This compound was obtained with a small amount (5-10%) of the corresponding phosphine oxide, see: Blackmond, D. G., Lightfoot, A., Pfaltz, A., Rosner, T., Schnider, P., Zimmermann, N. *Chirality* **2000**, *12*, 442-449.

¹H NMR spectra of Aryl Bromides




Table 1 Entry 3 Starting Material







Table 1 Entry 4 Starting Material







Table 1 Entry 5 Starting Material






Table 1 Entry 7 Starting Material





Table 1 Entry 8 Starting Material







Table 1 Entry 9 Starting Material







Table 1 Entry 10 Starting Material







Table 1 Entry 11 Starting Material







Table 1 Entry 12 Starting Material






Table 1 Entry 13 Starting Material







Table 1 Entry 14 Starting Material







Table 1 Entry 15 Starting Material









Table 1 Entry 16
Starting Material







¹H and ³¹P NMR Spectra of PHOX Derivatives

¹H NMR





Table 1 Entry 3 Product



³¹P NMR





Table 1 Entry 3 Product



¹H NMR





Table 1 Entry 4 Product



³¹P NMR





Table 1 Entry 4 Product



¹H NMR





Table 1 Entry 5 Product



³¹P NMR





Table 1 Entry 5 Product



¹H NMR





Table 1 Entry 6 Product



³¹P NMR





Table 1 Entry 6 Product



¹H NMR





Table 1 Entry 7 Product



³¹P NMR





Table 1 Entry 7 Product



¹H NMR





Table 1 Entry 8 Product



³¹P NMR





Table 1 Entry 8 Product



¹H NMR





Table 1 Entry 9 Product



³¹P NMR





Table 1 Entry 9 Product



¹H NMR





Table 1 Entry 10 Product



³¹P NMR





Table 1 Entry 10 Product



¹H NMR





Table 1 Entry 11 Product



³¹P NMR





Table 1 Entry 11 Product



¹H NMR





Table 1 Entry 12 Product



³¹P NMR





Table 1 Entry 12 Product



¹H NMR





Table 1 Entry 13 Product



³¹P NMR





Table 1 Entry 13 Product



¹H NMR





Table 1 Entry 14 Product



³¹P NMR





Table 1 Entry 14 Product



¹H NMR





Table 1 Entry 15 Product



³¹P NMR





Table 1 Entry 15 Product



¹H NMR





Table 2 Entry 1 Product



³¹P NMR





Table 2 Entry 1 Product



¹H NMR





Table 2 Entry 2 Product



³¹P NMR





Table 2 Entry 2 Product



¹H NMR





Table 2 Entry 5 Product



³¹P NMR





Table 2 Entry 5 Product



¹H NMR





Table 2 Entry 6 Product



³¹P NMR





Table 2 Entry 6 Product



¹H NMR





Table 2 Entry 7 Product



³¹P NMR





Table 2 Entry 7 Product



¹H NMR





Table 2 Entry 8 Product



³¹P NMR





Table 2 Entry 8 Product



¹H NMR





Table 2 Entry 3 Phosphine



³¹P NMR





Table 2 Entry 3 Phosphine



¹H NMR





Table 2 Entry 4 Phosphine



³¹P NMR





Table 2 Entry 4 Phosphine



¹H NMR





Table 2 Entry 3 Product



³¹P NMR





Table 2 Entry 3 Product



¹H NMR





Table 2 Entry 4 Product



³¹P NMR





Table 2 Entry 4 Product



¹H NMR





Table 2 Entry 3 Product, Free Phosphine



³¹P NMR






Table 2 Entry 3 Product, Free Phosphine



¹H NMR



³¹P NMR




Table 2 Entry 4 Product, Free Phosphine